Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Qingfei Dayuan Granule is a traditional Chinese medicine (TCM) herbal formulation developed as granules for oral administration. It is primarily used for the treatment of influenza and upper respiratory tract infections (URTIs), especially those characterized by pulmonary heat-toxin syndrome in TCM. The formulation contains multiple herbal ingredients and exerts its effects through multi-ingredient, multi-target actions including anti-inflammatory and immune-modulating activities[3][4]. Preclinical studies demonstrate significant anti-inflammatory and antitussive effects, with a favorable safety profile at clinically relevant doses[5]. Clinical trials have shown that it can shorten fever duration and alleviate symptoms such as sore throat, nasal congestion, sneezing, headache, and cough in patients with influenza or URTIs[6][7]. Mechanistically, network pharmacology analyses suggest that the granules act on inflammatory pathways and immune system modulation to exert their therapeutic effect[3][4].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Qingfei Dayuan Granule.